Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE

Abstract

**Background:** Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality resulting in increased healthcare cost. Association of psychotropic medications with ADRs is common. Pharmacovigilance can play a vital role in alerting the healthcare providers from the possible ADRs and thus protecting the patients receiving psychotropic medications.

**Aim:** To monitor and report the incidence and nature of ADRs in psychiatry outpatient department (OPD).

**Materials and Methods:** A prospective observational study was carried out in the psychiatry OPD. All the patients attending psychiatry outpatient and satisfying the inclusion criteria were monitored for ADRs. The causality, severity and preventability assessment of documented ADRs was done. Chi-square test was done to identify the association between ADRs and sociodemographic, disease and treatment-related variables. Paired Student’s t-test was carried out to compare the significance difference in the weight of the patients who reported weight gain to psychotropic medications.

**Results:** The incidence rate of ADR was found to be 10.2%. A total of 112 ADRs were documented. Weight gain 18 (16.07%) followed by somnolence 8 (7.14%) was the most commonly reported ADR. Atypical antipsychotics 37 (33.0%) were the most common class of psychotropic drugs implicated in ADRs. Escitalopram 16 (14.28%) followed by quetiapine 14 (12.5%) were associated with a maximum number of ADRs. No significant association ($P > 0.05$) documented between demographic and treatment-related variables with number of ADRs.

**Conclusion:** Study revealed a moderate incidence of ADRs in patients attending the psychiatry OPD. Majority of the ADRs reported during the study were mild in nature and not preventable type.

**Key words:** Adverse drug reaction, adverse drug reaction monitoring, pharmacovigilance, psychiatry outpatients, psychotropic medications

Introduction

Adverse drug reactions (ADRs) are known to be the significant cause of morbidity and mortality both inpatients and outpatients settings. The overall incidence of serious and fatal ADRs among hospitalized patients was found to be 6.7% and 0.32%, respectively. While in outpatient settings, the incidence of ADRs ranges from 5% to 35%. ADRs are recognized to be one the significant cause of hospital admissions and the incidence varied from 0.2% to 41.3%. ADR monitoring in a hospital setting is an important process.
to identify the patients who are at high risk for developing ADRs and understand the nature and incidence of ADRs in a local population.\textsuperscript{[5]} Thus, ADR monitoring helps in developing appropriate interventional strategies to manage, prevent and minimize the risk of developing ADRs and thereby reducing the cost of care.\textsuperscript{[6]}

The association of psychotropic medications with ADRs is common and can occur even at the normal doses used in the management of acute and maintenance phases of psychiatric disorders.\textsuperscript{[7]} These ADRs can impair quality of life, may lead to poor adherence to medications, cause physical morbidity, issue stigma, and in extreme cases, can be fatal.\textsuperscript{[6]} Many studies have reported the incidence, nature and occurrence of ADRs to various psychotropic medications.\textsuperscript{[7-9,11-13]} Good number of these studies has reported the incidence and nature of ADRs in patients visiting psychiatry outpatient departments (OPDs).\textsuperscript{[11-13]}

The study reported by Solanke et al. the overall incidence rate of ADRs was found to be 5.01\% in psychiatry OPD of a tertiary referral center in central India.\textsuperscript{[11]} Another study reported 429 (21.45\%) having, at least, one ADR among 2000 patients who were screened in psychiatry OPD.\textsuperscript{[9]} Psychiatric medications accounted for 45 (48.4\%) of the ADRs in hospitalized psychiatric patients as reported by Thomas et al.\textsuperscript{[13]} However, no published studies available regarding the incidence and nature of ADRs in psychiatry patients in UAE.

The awareness of the health care providers regarding ADRs of the psychotropic agents and how to manage them can foster the safe and rational use of these agents. In UAE, pharmacovigilance activity is still in its initial stages, and its importance is not very well recognized. Pharmacovigilance can play a vital role in alerting the healthcare providers from the possible ADRs and thus protecting the patients who are using psychotropic medications.\textsuperscript{[14]} Therefore, the ultimate goal of our study is to enhance and strengthen the pharmacovigilance activity in UAE and foster the role of clinical pharmacist in ADR monitoring and reporting.

The study aims to (1) monitor and estimate the incidence and nature of ADRs in psychiatry OPD of a Secondary Care Hospital in Ras Al-Khaimah, UAE, (2) assess the causality of documented ADRs, (3) evaluate the nature of ADRs based on preventability, predictability and severity and (4) analyze the ADRs according to the demographic, illness characteristics and predisposing factors.

Materials and Methods

The study was conducted at psychiatry OPD of Secondary Care Hospital of Ras Al-Khaimah, UAE. This was a prospective observational study conducted from October 2013 to April 2014. The study was approved by Research and Ethics Committee. Patients of all age groups and both the gender, diagnosed with any psychiatric disorder and receiving psychotropic medications and registered in the psychiatry OPD of the study site were monitored for ADRs and were included in the study.

Patients who were not prescribed with any psychotropic medications, suffering from malignancies, terminally ill, and drug abusers (due to the reason that they receive multiple medications, and it is more difficult to get correct conclusion regarding ADRs in these group of patients) and mentally retarded as they cannot illustrate/mention their ADRs correctly were excluded from the study.

All the patients attending psychiatry outpatient and satisfying the inclusion criteria were monitored for ADRs on four fixed days in a week by the study investigators from 09:00 a.m. to 01:00 p.m. During the study period, a total of 900 patients were expected to be monitored for ADRs. ADRs noticed by the treating psychiatrist, reported by the patient or their caretakers during regular patient consultation were documented by the clinical pharmacist. The required data was collected from the patient case files as well as from the patients themselves and their caretakers if required and was entered in the designed ADR reporting and documentation form, which includes various details such as demographic information, disease characteristics, history of ADR, medication history, and other relevant information.

The causality assessment of documented ADRs was done using Naranjo scale,\textsuperscript{[10]} and WHO-The Uppsala Monitoring Centre probability scale,\textsuperscript{[11]} severity was assessed using Hartwig et al. scale,\textsuperscript{[7]} and preventability assessment using Modified Schumock and Thornton’s Scale.\textsuperscript{[12]}

Type of underlying disorders in patients who experienced ADRs was classified according to International Classification of Diseases Ninth Revision, Clinical Modification. Drugs and system organ class involved in ADRs were coded according to Anatomical Therapeutic Chemical Classification System and World Health Organization Adverse Reaction Terminology respectively.

Data analysis

Collected data were summated and were entered into the Microsoft-excel sheet and was analyzed using the Statistical Package for the Social Sciences (SPSS) version 18.0. (IBM, Armonk, NY, United States of America). The categorical data were presented in the form of frequency, percentage, and mean ± standard deviation Chi-square test was performed to find out the association between ADRs and sociodemographic, disease and treatment-related variables. Paired Student’s t-test was performed to compare the significance difference in the weight of the patients who reported weight gain to psychotropic medications. P < 0.05 is considered as statistically significant. The results were presented in the form of text, tables, and figures.

Results

A total of 714 patients were monitored, of which 352 (49.2%) were male and 362 (50.7%) were female patients. Among the 73 patients who experienced ADR to psychotropic medications, 37 (50.7\%) were males and 36 (49.3\%) were females [Table 1]. The average age of the patients who experienced ADR was 36.15 ± 18.7 years. The maximum numbers of ADRs were documented in the age group of 18–28 years (30.1\%).
followed by 29–39 years (27.4%) [Table 2]. A total of 714 psychiatric patients visiting psychiatric OPD of the study site were reviewed during the study period, of which 73 patients experienced, at least, one ADR. The incidence of ADRs at outpatient psychiatry department was found to be (73/714 × 100) 10.2%. The average number of drugs taken by the patients who experienced, at least, one suspected ADR was found to be 2.7 ± 1.5 drugs. Majority of the patients who experienced ADR were taking one to two drugs (n = 40, 54.8%) [Table 1]. A total of 112 ADRs were observed during the study period. The overall mean number of ADRs documented in the study was found to be 1.5 ± 0.7 ADRs. Majority of the patients 46 (63.0%) experienced at least one ADR [Table 1].

Weight gain 18 (16.07%) was the most commonly suspected ADR followed by somnolence 8 (7.14%), constipation, dry mouth and headache 06 (5.3%) each [Tables 2 and 2a]. Weight gain has been reported in 18 cases. However, the weight (pre- and post-treatment) details of only 12 patients were available during documentation. The average weight of the patients before initiating psychotropic drugs was found to be 65.7 ± 14.1 kg, whereas after receiving suspected psychotropic therapy, it was found to be 78.9 ± 15.9 kg. This difference in the weight of the patients after receiving the suspected psychotropic treatment was found to be highly significant (P < 0.001) [Table 3]. Escitalopram 16 (14.2%) was the most commonly implicated drug in ADR followed by quetiapine 13 (11.6%) and olanzapine and fluoxetine 10 (8.9%) each [Table 4]. Atypical antipsychotics 37 (33%) followed by selective serotonin reuptake inhibitors (SSRIs) 34 (30.3%) were the most commonly involved psychotropic medications involved in ADRs [Table 5]. Depression 27 (24.10%) was the most commonly diagnosed psychiatric condition in patients who developed ADRs followed by obsessive-compulsive disorder in 18 (16.07%) cases [Table 6]. Central nervous system (CNS) 33 (29.5%) was the most commonly affected organ due to ADRs followed by gastrointestinal system 26 (23.2%) [Table 7].

Majority of the suspected ADRs were possible in nature 60 (53%) followed by probable type 38 (34%) [Table 8]. Majority of the

### Table 1: Demographic and treatment-related variables of the patients who experienced adverse drug reactions

| Demographic and treatment-related variables | n (%) | Total=73 |
|-------------------------------------------|-------|----------|
| Gender                                    |       |          |
| Male                                      | 37 (50.7) |
| Female                                    | 36 (49.3) |
| Age (in years)                            |       |          |
| > 18                                      | 07 (9.6) |
| 18–28                                     | 22 (30.1) |
| 29–39                                     | 20 (27.4) |
| 40–49                                     | 11 (15.1) |
| > 60                                      | 09 (12.3) |
| Nationality                               |       |          |
| Arab                                      | 72 (98.7) |
| Non-Arab                                  | 01 (1.3) |
| Prescribed number of drugs                |       |          |
| 1–2                                       | 40 (54.8) |
| 3–4                                       | 24 (32.9) |
| > 05                                      | 09 (12.3) |
| Number of ADRs documented/patient         |       |          |
| 01                                        | 46 (63.0) |
| 02                                        | 16 (21.9) |
| 03                                        | 11 (15.1) |

ADR: Adverse drug reactions

### Table 2: Spectrum of different adverse drug reactions and drug(s) implicated

| Type of ADRs   | n (%) (n=112) | Drug(s) implicated                                                                 |
|----------------|---------------|-----------------------------------------------------------------------------------|
| Weight gain    | 18 (16.07)    | Quetiapine (n=6), olanzapine (n=3), escitalopram (n=2), mirtazapine (n=2), clomipramine (n=2), paroxetine (n=1), risperidone (n=1), aripiprazole (n=1) |
| Somnolence     | 08 (7.14)     | Quetiapine (n=2), olanzapine (n=2), valproic acid (n=1), clozapine (n=1), mirtazapine (n=1), fluoxetine (n=1) |
| Constipation   | 06 (5.35)     | Venlafaxine (n=2), clomipramine (n=2), valproic acid (n=1), risperidone (n=1) |
| Dry mouth      | 06 (5.35)     | Quetiapine (n=4), valproic acid (n=1), aripiprazole (n=1) |
| Headache       | 06 (5.35)     | Venlafaxine, clozapine, gabapentin, paroxetine, methylphenidate, carbamazepine (1 each) |
| Decreased appetite | 05 (4.46) | Methylphenidate (n=2), fluoxetine (n=1), risperidone (n=1), atomoxetine (n=1) |
| Insomnia       | 05 (4.46)     | Fluoxetine, escitalopram, venlafaxine, aripiprazole, olanzapine (1each) |
| Irritability   | 05 (4.46)     | Escitalopram (n=2), paroxetine (n=1), fluoxetine (n=1), aripiprazole (n=1) |
| Dizziness      | 04 (3.57)     | Fluoxetine (n=2), paroxetine (n=1), carbamazepine (n=1) |
| Nausea         | 03 (2.67)     | Fluoxetine, escitalopram, carbamazepine (1 each) |
| Abdominal pain | 03 (2.67)     | Escitalopram (n=2), methylphenidate (n=1) |
| Tremor         | 03 (2.67)     | Venlafaxine, paroxetine, haloperidol (1 each) |
| Impaired memory | 03 (2.67)   | Carbamazepine (n=3) |
| Restlessness   | 03 (2.67)     | Aripiprazole, escitalopram, olanzapine (1 each) |
| Postural hypotension | 03 (2.67) | Alprazolam, clomipramine, escitalopram (1 each) |
| Sexual dysfunction | 02 (1.78) | Paroxetine, quetiapine (1 each) |
| Increased appetite | 02 (1.78) | Paroxetine, escitalopram (1 each) |
| Anxiety        | 02 (1.78)     | Fluoxetine (n=2) |
| Acne           | 02 (1.78)     | Carbamazepine, clomipramine (1 each) |
| Diabetes mellitus | 02 (1.78) | Olanzapine (n=2) |

ADR: Adverse drug reactions
Table 2a: Spectrum of other adverse drug reactions and drug (s) implicated

| Type of ADRs                  | n (%) (n=112) | Drug (s) implicated       |
|------------------------------|---------------|---------------------------|
| Hypersexual behavior         | 01 (0.89)     | Escitalopram              |
| Loss of interest in sex      | 01 (0.89)     | Escitalopram              |
| Amenorrhea                   | 01 (0.89)     | Valproic acid             |
| Cystitis                     | 01 (0.89)     | Valproic acid             |
| Dystonia                     | 01 (0.89)     | Olanzapine                |
| Tardive dyskinesia           | 01 (0.89)     | Clonazepam                |
| Akathisia                    | 01 (0.89)     | Risperidone               |
| Hypertension                 | 01 (0.89)     | Atomoxetine               |
| Tachycardia                  | 01 (0.89)     | Atropine                  |
| Bradycardia                  | 01 (0.89)     | Escitalopram              |
| Palpitation                  | 01 (0.89)     | Paroxetine                |
| Tinnitus                     | 01 (0.89)     | Escitalopram              |
| Taste perversion             | 01 (0.89)     | Valproic acid             |
| Agitation                    | 01 (0.89)     | Fluoxetine                |
| Numbness                     | 01 (0.89)     | Methylphenidate           |
| Skin lesions                 | 01 (0.89)     | Carbamazepine             |
| Abnormal thinking            | 01 (0.89)     | Risperidone               |
| Automatism                   | 01 (0.89)     | Risperidone               |
| Odd behavior                 | 01 (0.89)     | Valproic acid             |
| Hallucination                | 01 (0.89)     | Quetiapine                |
| Neck/shoulder pain           | 01 (0.89)     | Escitalopram              |

ADR: Adverse drug reaction

Table 3: Body weight profile of the patients who reported weight gain

| Weight of the patients | n  | Mean±SD (in kg) | df | Significant (two-tailed) |
|------------------------|----|-----------------|----|--------------------------|
| Pretreatment           | 12 | 65.7±14.1       | 11 | P<0.001**                |
| Posttreatment          | 12 | 78.9±15.9       | 11 |                          |

**P<0.001 is considered statistically highly significant by t-test. SD: Standard deviation

Table 4: Psychotropic drugs associated with adverse drug reactions

| Name of the drug                  | n (%) (n=112) |
|-----------------------------------|---------------|
| Escitalopram                      | 16 (14.28)    |
| Quetiapine                        | 14 (12.5)     |
| Olanzapine, fluoxetine            | 10 (8.9) each |
| Carbamazepine, paroxetine         | 08 (7.1) each |
| Valproic acid                     | 07 (6.2)      |
| Risperidone, clomipramine         | 06 (5.3) each |
| Venlafaxine, aripiprazole, methylphenidate | 05 (4.4) each |
| Mirtazapine, atomoxetine          | 03 (2.6) each |
| Clozapine                         | 02 (1.7)      |
| Haloperidol, alprazolam, clonazepam, gabapentin | 01 (0.89) each |

Table 5: Different class of psychotropic drugs involved in adverse drug reactions

| Class of psychotropic drugs       | n (%) of ADR (n=112) |
|-----------------------------------|----------------------|
| Antipsychotics                    |                      |
| Atypical antipsychotics           | 37 (33.0)            |
| Typical antipsychotics            | 01 (0.89)            |
| Antidepressants                   |                      |
| Tricyclic antidepressants         | 06 (5.3)             |
| Tetracyclic antidepressants       | 03 (2.6)             |
| Selective serotonin reuptake inhibitors | 34 (30.3)       |
| Selective norepinephrine reuptake inhibitors | 05 (4.4)    |
| Antiepileptics                    | 16 (14.3)            |
| Central nervous system stimulants | 05 (4.4)             |
| Norepinephrine reuptake inhibitors | 03 (2.6)           |
| Anxiolytics                       | 02 (1.7)             |

ADR: Adverse drug reaction

Table 6: Type of underlying disorders in patients who experienced adverse drug reactions

| Psychiatric disorders             | n (%) of ADR (n=112) |
|-----------------------------------|----------------------|
| Depression                        | 27 (24.10)           |
| Obsessive compulsive disorder     | 18 (16.07)           |
| Epilepsy                          | 15 (13.39)           |
| Schizophrenia                     | 13 (11.60)           |
| Bipolar-mania                     | 08 (7.14)            |
| Generalized anxiety disorder      | 06 (5.25)            |
| Attention deficit hyeractivity disorder | 05 (4.46)     |
| Depression and anxiety            | 05 (4.46)            |
| Dementia                          | 05 (4.46)            |
| Autism spectrum disorder          | 04 (3.57)            |
| Panic disorder                    | 03 (2.67)            |
| Stuttering                        | 02 (1.78)            |
| Somatization disorder             | 01 (0.89)            |

ADR: Adverse drug reaction

Table 7: Organ systems associated with adverse drug reactions

| System organ class (WHO-ART SOC code) | n (%) (n=112) |
|--------------------------------------|---------------|
| Central and peripheral nervous system disorders (0410) | 33 (29.5) |
| Gastro-intestinal system disorders (0600) | 26 (23.2) |
| Metabolic and nutritional disorders (0800) | 20 (17.9) |
| Psychiatric disorders (0500) | 15 (13.4) |
| Cardiovascular disorder (1010) | 04 (3.6) |
| Heart rate and rhythm disorder (1030) | 03 (2.7) |
| Skin and appendages disorder (0100) | 03 (2.7) |
| Reproductive system disorders male (1410) | 03 (2.7) |
| Reproductive system disorders female (1420) | 02 (1.7) |
| Hearing and vestibular Disorders (0432) | 01 (0.9) |
| Musculoskeletal disorder (0200) | 01 (0.9) |
| Urinary system disorders (1300) | 01 (0.9) |

SOC: System-organ classification, WHO-ART: World Health Organization-Adverse Reaction Terminology

suspected ADRs were possible 51 (45.5%) in nature followed by probable type 39 (34.9%) [Table 8]. Severity assessment of suspected ADRs was done using Hartwig’s severity assessment. Majority of the suspected ADRs were mild in nature 98 (87%) followed by moderate type 14 (13%) [Table 8]. Preventability assessment of suspected ADRs was done using Modified Schumock and Thornton scale. Majority of the suspected ADRs 92 (82.1%) were of not preventable type followed by probably preventable 17 (15.17%) [Table 8].
In majority of the cases the drug was withdrawn 46 (41.1%) to manage ADRs followed no change in the prescribed psychotropic medications 37 (33.0%) [Table 9]. In majority of the suspected, ADRs were treated symptomatically 45 (40.2%) followed by no treatment in 36 (32.1%) cases [Table 9]. Majority of the suspected ADRs 52 (46.4%) were recovered followed by continuation of suspected ADR in 38 (34.0%) cases [Table 9]. For majority of the cases, no dechallenging was done 60 (53.6%) followed by definite improvement of ADRs in 44 (39.2%) cases after dechallenging. While no rechallenge was done for majority of 104 (92.9%) suspected ADRs [Table 9].

A Pearson Chi-square test was conducted to examine whether there was a relationship between demographic/treatment related variables with the number of suspected ADRs. The results showed that there was no significant relationship between gender ($\chi^2 = 0.89$, df = 2, $P = 0.66$), age ($\chi^2 = 10.87$, df = 10, $P = 0.36$), nationality status ($\chi^2 = 0.59$, df = 4, $P = 0.74$) and prescribed number of medications ($\chi^2 = 3.24$, df = 4, $P = 0.51$).

**Discussion**

The overall incidence rate of ADRs in our study was found to be 10.2%. However, many international studies have reported an overall incidence rate of 5.01–21.45% in psychiatry OPDs.\[^7\]–\[^11\] In contrast to our findings, a study conducted by Shah and Mehta reported an incidence rate of 0.67% in psychiatry outpatients.\[^10\]

Weight gain was the most commonly implicated ADR in the present study. Many ADR related studies conducted in this area have reported weight gain as one of the most commonly observed ADR in patients taking a certain class of psychotropic medications.\[^10\]–\[^12\] In our study, majority of the weight gain were documented for atypical antipsychotics, followed by SSRIs, selective noradrenaline reuptake inhibitors, and tricyclic antidepressants. As reported in the literature the possible mechanisms for weight gain include 5HT₂ antagonism, H₁ antagonism, hyperprolactinemia and increased serum leptin.\[^13\] Furthermore, improvement of the underlying mental disorder like depression could lead to increase appetite and weight gain. It is suggested that switching the medication or psychotherapy, education, and healthy lifestyle will be beneficial in treating the drug-induced weight gain.\[^14\]

Somnolence/sedation/oversleep was the second most common ADR documented in our study. However, few studies have reported tremor as the most commonly noted ADR followed by weight gain.\[^7\]–\[^8\] This difference in the findings could be due to the difference in the prescribing pattern of psychotropic medications and may be influenced by the number and type of psychiatric patients visiting the OPD as reported in other ADR monitoring studies.\[^10\]

CNS adverse effects such as somnolence/sedation are common with psychotropic medications because these drugs act on CNS. It is documented that sedation persists for first few months, but usually wears off.\[^15\] It is noteworthy to mention that apart from the well-known ADRs, we noticed two additional ADRs, where occurrence or incidences of which has not been well documented or reported in any standard literatures. One such ADR is hypersexual behavior and the other one is total loss of interest in sex reported by a female

---

**Table 8: Causality assessment of suspected adverse drug reactions**

| Assessment                          | $n$ (% of ADR) |
|-------------------------------------|----------------|
| Naranjo causality assessment        |                |
| Definite                            | 10 (08)        |
| Probable                            | 38 (34)        |
| Possible                            | 60 (53.5)      |
| Doubtful                            | 04 (3.5)       |
| WHO probability assessment          |                |
| Certain                             | 16 (14.3)      |
| Probable                            | 39 (34.9)      |
| Possible                            | 51 (45.5)      |
| Unclassifiable                      | 01 (0.9)       |
| Unlikely                            | 02 (1.8)       |
| Conditional                         | 03 (2.7)       |
| Preventability assessment           |                |
| Not preventable                     | 92 (82.1)      |
| Probably preventable                | 17 (15.2)      |
| Definitely preventable              | 03 (2.7)       |

ADR: Adverse drug reaction, WHO: World Health Organization

**Table 9: Outcome of suspected adverse drug reactions**

| Outcome                        | $n$ (% of ADR) |
|--------------------------------|----------------|
| Management of suspected ADRs   |                |
| Drug withdrawal                | 46 (41.1)      |
| Does altered                   | 29 (25.9)      |
| No change                      | 37 (33.0)      |
| Treatment of suspected ADRs    |                |
| Specific                       | 31 (27.7)      |
| Symptomatic                    | 45 (40.2)      |
| Nil                            | 36 (32.1)      |
| Outcome of suspected ADRs      |                |
| Fatal                          | 00 (00)        |
| Recovery                       | 52 (46.4)      |
| Continuing                     | 38 (34.0)      |
| Partial improvement            | 16 (14.2)      |
| Unknown                        | 06 (05.4)      |
| Dechallenge of suspected ADRs  |                |
| Unknown                        | 03 (2.7)       |
| No improvement                 | 05 (4.5)       |
| Definite improvement           | 44 (39.2)      |
| No dechallenge                 | 60 (53.6)      |
| Rechallenge of suspected ADRs  |                |
| No occurrence                  | 00 (00)        |
| Recurrence of symptom          | 08 (7.1)       |
| No rechallenge                 | 104 (92.9)     |

ADRs: Adverse drug reactions
and male patient respectively. Interestingly, both these ADRs were reported for escitalopram. It is well documented in the literature that escitalopram causes decreased libido (3–7%) and impotence (2–3%), but hypersexual behavior and total loss of interest in sex are not well documented.[50] However, further examination on this issue could be helpful in determining the exact reason or to confirm whether such behavior is psychiatry disorder related. Decrease libido and impotence are both common in depression and would respond to escitalopram which could explain the hypersexuality reported or due to drug. The male patient, who reported having loss of interest in sex, denied having impotence.

Another two rare ADRs noticed in the study were restlessness to olanzapine, which is documented in the adolescent population. However, in this study, it was reported by a geriatric patient could be akathisia, which is a common side effect with antipsychotics and in another incidence automatism, which is most commonly documented in children, but it was reported by an adult schizophrenic patient.

One more important observation documented in the current study was out of 112 suspected ADRs, the incidence of 16 ADRs were <1%. Examples of such ADRs include tardive dyskinesia, which is a remote side effect and shown only after years associated with clozapine. It was observed that limited numbers of patients were on clozapine.[59] In addition, we noticed two unusual ADRs such as dystonia implicated with olanzapine and restlessness and irritability due to escitalopram usage.

Majority of the suspected ADRs were possible in nature. While good number of ADRs were mild in nature and were of not preventable type. A study conducted by Prajapati et al. reported higher number of ADRs, which were moderate in nature.[61] However, few other studies have reported higher number of ADRs, which are mild in nature.[62] In contrast, several studies have reported serious or fatal ADRs to a different class of psychotropic medications such as antidepressants and atypical antipsychotic medications.[53–55] A recent study has reported that even ADR, which is “not severe” in nature can have a significant impact on patients with psychiatry illness.[56] Hence, managing and preventing ADR in psychiatric illness patients is vital.

Majority of the suspected ADRs were not of preventable type. In contrast to our findings, a study conducted by Nithya et al. reported that all the ADRs to psychotropic drugs were not preventable type.[61] In another study conducted by Lahon et al. good number of the ADRs were probably preventable.[22] While another study assessing the preventability of ADR reported only 19 preventable ADRs among 94 suspected ADRs.[13] Another study highlighted the role of the pharmacist in preventing ADRs and 87 pharmacist interventions were recognized as preventable ADRs.[57]

As reported in the literature occurrence of ADR may lead to nonadherence to medications.[8] In the present study, we noticed five patients out of 73, who have stopped their medication on their own at home after the development of ADR. This observation supports the fact that ADR might lead to nonadherence or discontinuation of therapy.

Age, gender, number of drugs received/polypharmacy and race are known to be the predisposing factors of ADRs.[58] In contrast to our findings, a study conducted by Kasper et al. identified age and male sex as the indicators of tardive dyskinesia in schizophrenia patients.[59] This study was limited only to ADR such as tardive dyskinesia.

The main limitation of the present study was short duration of the study period. Study duration of more than 1 year could be more beneficial in identifying the wide spectrum of ADRs to wide variety of medications. In addition, majority of the ADRs identified during study duration were mild in nature. No fatal/serious ADRs were reported or documented in the outpatient clinic, as the patients who develop serious ADRs will be admitted to emergency room directly followed by inpatient department. No rechallenging was done or was possible for majority of the ADRs. Our study did not document and categorize the type and number of ADRs based on the duration of use of medication and new versus old patients. It was difficult to obtain required information from few patients who were non-Arabic and non-English (not fluent) speakers. In the present study, the outpatient type was mainly limited to nationals, students below 18 years of age and to those patients who have a health care facility. This resulted in limiting the number of patients visiting the OPD of the study site.

Conclusion

The present study offers a representative profile of the ADRs which can be expected in the psychiatry outpatients department in UAE. The study revealed a moderate incidence of ADRs in patients attending the psychiatry OPD. Majority of the ADRs reported during the study were mild in nature and not preventable type. Good number of the ADRs recovered upon withdrawal of the drug or after dose is altered. The study fosters the role of clinical pharmacist in the monitoring and reporting of ADRs. Regular intensive monitoring of ADRs in psychiatry OPD settings by clinical pharmacist might help in early detection of ADRs and reduce the risk caused by ADRs and thereby it may improve the quality of care, reduction in the treatment cost and enhancement of medication adherence pattern among patients.

Acknowledgment

Our sincere thanks to Dr. Padma G. M. Rao, Associate Dean and Chairperson of Department of Clinical Pharmacy and Pharmacology of RAK College of Pharmaceutical Sciences (RAKOPS), RAK Medical and Health Sciences University (RAKMHSU) for all the help and encouragement during the study period. We are also grateful to Dr. B. G. Nagavi, Dean, and RAKOPS for all the support and cooperation. Our heartfelt thanks to Dr. Gurumadhva Rao, Vice Chancellor of RAKMHSU for all the support, encouragement, and motivation. We thank Medical Director of Ibrahim Bin Hamad Obaidallah Hospital and the medical and nursing staff of Psychiatry Department for their kind help and cooperation during the study period.
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions – A meta-analysis. PLoS One 2012;7:e33236.

2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.

3. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Amnest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66.

4. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): A meta-analysis of observational studies. Pharm World Sci 2002;24:46-54.

5. Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacolet Res 2006;54:226-33.

6. Rajakannan T, Mallayasamy S, Guddattu V, Kamath A, Vilakkhthala R, Rao PG, et al. Cost of adverse drug reactions in a South Indian tertiary care teaching hospital. J Clin Pharmacol 2012;52:559-65.

7. Sengupta G, Bhownick S, Hazra A, Datta A, Rahaman M. Adverse drug reaction monitoring in psychiatric out-patient department of an Indian teaching hospital. Indian J Pharmacol 2011;43:36-9.

8. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 2007;21:911-36.

9. Prajapati HK, Joshi ND, Trivedi HR, Parmar MC, Jadav SP, Parmar DM, et al. Adverse drug reaction monitoring in psychiatric outpatient department of a tertiary care hospital. Natl J Integr Res Med 2013;4:102-6.

10. Mishra S, Swain TR, Mohanty M. Adverse drug reaction monitoring of antidepressants in the psychiatry outpatients department of a tertiary care teaching hospital. J Clin Diagn Res 2013;7:1131-4.

11. Solanke B, Mahatme MS, Dakhale G, Hivare S, Shrivastava M, Waradkar P. Adverse drug reaction profile at psychiatry out-patient department of a tertiary referral centre in Central India. Int J Basic Clin Pharmacol 2013;2:341-3.

12. Pahari N, Tripathi SK, Maity T, Gupta BK, Bagchi C, Mondal DK. Evaluation and analysis of adverse drug reactions of second generation antipsychotics in a psychiatry out-patient department. Int J Pharm Sci 2012;4:158-62.

13. Thomas M, Boggs AA, DiPaula B, Siddiqi S. Adverse drug reactions in hospitalized psychiatric patients. Ann Pharmacother 2010;44:819-25.

14. Faich GA. US adverse drug reaction surveillance 1989-1994. Pharmacoeconomics Drug Saf 1996;5:393-9.

15. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.

16. The Use of the WHO-UMC System for Standardized Case Causality Assessment. Available from: http://www.WHO-UMC.org/graphics/4409.pdf. [Last accessed on 2012 Mar 12].

17. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.

18. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538.